Along the same lines of inquiry, treatment of diabetic post-MI mice with the DPP-4 inhibitor sitagliptin, which augments concentrations of endogenous full-length GLP-1, reduced mortality and improved cardiac function [40]. The gene discussed is GCG; the disease is myocardial infarction.